Nishikawa Masatomo, Miyake Hideaki, Fujisawa Masato
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Urol Oncol. 2016 Sep;34(9):417.e9-417.e15. doi: 10.1016/j.urolonc.2016.04.001. Epub 2016 May 11.
To evaluate the prognostic significance of preoperatively assessed aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), and the AST/ALT (De Ritis) ratio in patients with upper urinary tract urothelial carcinoma (UUTUC).
This study included a total of 109 consecutive patients with clinically localized UUTUC who underwent nephroureterectomy. Effects of preoperative levels of AST, ALT, and the De Ritis ratio in addition to conventional clinicopathological parameters on the extravesical recurrence-free survival (eRFS) in these 109 patients were retrospectively analyzed.
Despite the lack of a significant correlation of AST or ALT with any of the factors examined in this study, the elevation of the De Ritis ratio was significantly correlated with several unfavorable parameters, including elderly age, high pathological stage, high tumor grade, and lymphovascular invasion. During the observation period of this series (median = 40.8mo), extravesical disease recurrence developed in 39 (35.8%) of the 109 patients, with a 5-year eRFS rate of 56.8%. Of several factors examined, the tumor location, De Ritis ratio, pathological stage, lymph node metastasis, tumor grade, lymphovascular invasion, surgical margin status, and adjuvant chemotherapy were shown to be significantly correlated with eRFS by univariate analysis. Of these, the De Ritis ratio, pathological stage, lymph node metastasis, and tumor grade were identified as independent predictors of eRFS on multivariate analysis.
These findings suggest that preoperative assessment of the De Ritis ratio may provide useful information with respect to the clinical course of patients with clinically localized UUTUC who are scheduled to be treated with nephroureterectomy.
评估术前测定的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)及AST/ALT(德瑞蒂斯)比值在上尿路尿路上皮癌(UUTUC)患者中的预后意义。
本研究共纳入109例接受肾输尿管切除术的临床局限性UUTUC患者。回顾性分析这109例患者术前AST、ALT水平及德瑞蒂斯比值,以及传统临床病理参数对膀胱外无复发生存期(eRFS)的影响。
尽管AST或ALT与本研究中检测的任何因素均无显著相关性,但德瑞蒂斯比值升高与几个不良参数显著相关,包括老年、高病理分期、高肿瘤分级和淋巴管浸润。在本系列观察期(中位数=40.8个月)内,109例患者中有39例(35.8%)发生膀胱外疾病复发,5年eRFS率为56.8%。单因素分析显示,所检测的几个因素中,肿瘤部位、德瑞蒂斯比值、病理分期、淋巴结转移、肿瘤分级、淋巴管浸润、手术切缘状态及辅助化疗与eRFS显著相关。其中,多因素分析确定德瑞蒂斯比值、病理分期、淋巴结转移和肿瘤分级为eRFS独立预测因素。
这些发现表明,术前评估德瑞蒂斯比值可能为计划接受肾输尿管切除术治疗的临床局限性UUTUC患者的临床病程提供有用信息。